Experts come together to share their perspective on the paradigm of previously treated Ph+ chronic myeloid leukemia.
December 14th 2021
Expert overview of chronic myeloid leukemia, including considerations for the unmet needs in management as they exist today.
January 19th 2022
Shared insight on chromosomal abnormalities and genetic alterations that influence the disease course and management of CML.
Key opinion leader perspectives on assessing a patient’s response to therapy for chronic myeloid leukemia.
January 26th 2022
Daniel DeAngelo, MD, PhD, highlights the role that tyrosine kinase inhibitors play in the CML treatment paradigm.
Considerations for selecting optimal second-line therapy for chronic myeloid leukemia when a patient progresses.
February 2nd 2022
A brief review of the inherent challenges in guiding patients through several lines of therapy for chronic myeloid leukemia.
Jorge Cortes, MD, breaks down third-line treatment options for patients who progress with chronic myeloid leukemia.
February 9th 2022
Shared insight on asciminib’s role in chronic myeloid leukemia in light of available clinical data.
Experts share their personal experience with asciminib as later-line therapy for patients with chronic myeloid leukemia.
February 16th 2022
A brief review of asciminib’s toxicity profile and how to best manage adverse events in patients with chronic myeloid leukemia.